The re-opened comment period for feedback to the US Food and Drug Administration on direct-to-consumer genetic testing ends today. The panel focused on molecular and clinical genetics, which is part of the medical devices committee, is seeking “input and comments from interested stakeholders to discuss scientific issues concerning DTC tests,” according to the Federal Register. At Genomes Unzipped, Luke Jostins urges his readers to share their thoughts with FDA. "The FDA needs to hear the full diversity of opinions and facts on this subject to make an informed decision," he writes. An older blog post from Dan Vorhaus at the Genomic Law Report adds that FDA will be following this comment period with town hall-style meetings, including one this week in Orlando, Fla.
Premium Trial: